WO2008113965A1 - Indolizine acetic acid derivatives as crth2 antagonists - Google Patents

Indolizine acetic acid derivatives as crth2 antagonists Download PDF

Info

Publication number
WO2008113965A1
WO2008113965A1 PCT/GB2007/000996 GB2007000996W WO2008113965A1 WO 2008113965 A1 WO2008113965 A1 WO 2008113965A1 GB 2007000996 W GB2007000996 W GB 2007000996W WO 2008113965 A1 WO2008113965 A1 WO 2008113965A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetic acid
cyano
chloro
methylindolizin
compound
Prior art date
Application number
PCT/GB2007/000996
Other languages
French (fr)
Inventor
George Hynd
Nicholas Charles Ray
Harry Finch
John Gary Montana
Michael Colin Cramp
Trevor Keith Harrison
Rosa Arienzo
Paul Blaney
Yann Griffon
David Middlemiss
Original Assignee
Argenta Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07732088A priority Critical patent/EP2136804A1/en
Application filed by Argenta Discovery Limited filed Critical Argenta Discovery Limited
Priority to EA200970875A priority patent/EA200970875A1/en
Priority to MX2009010068A priority patent/MX2009010068A/en
Priority to CA002681409A priority patent/CA2681409A1/en
Priority to AU2007349641A priority patent/AU2007349641A1/en
Priority to US12/530,929 priority patent/US20100137300A1/en
Priority to JP2009554075A priority patent/JP2010522149A/en
Priority to BRPI0721477-4A priority patent/BRPI0721477A2/en
Priority to PCT/GB2007/000996 priority patent/WO2008113965A1/en
Priority to CN200780052278A priority patent/CN101678009A/en
Publication of WO2008113965A1 publication Critical patent/WO2008113965A1/en
Priority to IL201090A priority patent/IL201090A0/en
Priority to NO20093039A priority patent/NO20093039L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • This invention relates to specific indolizine compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), and their use in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component.
  • CRTH2 receptor Cellular Receptor-homologous molecule expressed on T Helper cells type 2
  • Mast cells are known to play an important role in allergic and immune responses through the release of a number of mediators, such as histamine, leukotrienes, cytokines, prostaglandin D 2 , etc (Boyce; Allergy Asthma Proc, 2004, 25, 27-30).
  • Prostaglandin D 2 (PGD 2 ) is the major metabolite produced by the action of cyclooxygenase on arachadonic acid by mast cells in response to allergen challenge (Lewis et al; J. Immunol., 1982, 129, 1627-1631). It has been shown that PGD 2 production is increased in patients with systemic mastocytosis (Roberts; N. Engl. J.
  • PGD 2 mediates it effects through two receptors, the PGD 2 (or DP) receptor (Boie et al; J. Biol. Chem., 1995, 270, 18910-18916) and the chemoattractant receptor- homologous molecule expressed on Th2 (or CRTH2) (Nagata et al; J. Immunol., 1999, 162, 1278-1289; Powell; Prostaglandins Luekot. Essent. Fatty Acids, 2003, 69, 179-185). Therefore, it has been postulated that agents that antagonise the effects of PGD 2 at its receptors may have beneficial effects in a number of disease states.
  • the CRTH2 receptor has been shown to be expressed on cell types associated with allergic inflammation, such as basophils, eosinophils, and Th2-type immune helper cells (Hirai et al; J. Exp. Med., 2001 , 193, 255-261).
  • the CRTH2 receptor has been shown to mediate PGD 2 -mediated cell migration in these cell types (Hirai et al; J. Exp. Med., 2001 , 193, 255-261), and also to play a major role in neutrophil and eosinophil cell recruitment in a model of contact dermatitis (Takeshita et al; Int. Immunol., 2004, 16, 947-959).
  • R 1 , R 2 , R3 and R 4 each independently are hydrogen, CrC 6 alkyl, fully or partially fluorinated C r C 6 alkyl, halo, -S(O) n R 10 , -SO 2 N(R 10 ) 2 , -N(R 10 ) 2 , -C(O)N(R 10 ) 2 , - NR 10 C(O)R 9 , -CO 2 R 10 , -C(O)R 9 , -NO 2 , -CN Or -OR 11 ; wherein each R 9 is independently d-C ' ⁇ alkyl, aryl, heteroaryl;
  • R 10 is independently hydrogen, CrC 6 alkyl, aryl, or heteroaryl
  • Ri 1 is hydrogen, CrC 6 alkyl, fully or partially fluorinated C
  • n 0, 1 or 2;
  • R 5 is CrC 6 alkyl, fully or partially fluorinated C r C 6 alkyl, Ci-C 6 alkenyl, CrC 6 alkynyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 6 is hydrogen, C r C 6 alkyl or fully or partially fluorinated d-C 6 alkyl;
  • R 7 and R 8 are independently hydrogen or Ci-C 6 alkyl, or R 7 and R 8 together with the atom to which they are attached form a cycloalkyl group; and
  • X is -CHR 6 -, -S(O) n -, -C(O)-, -NR 6 SO 2 - or -SO 2 NR 6 - wherein n is 0, 1 or 2.
  • the present invention provides a group of specific compounds falling within the scope of, but not specifically disclosed in our copending application PCT/GB2006/003394 referred to above.
  • the invention provides a compound selected from the group consisting of
  • Compounds with which the invention is concerned are CRTH2 receptor antagonists.
  • a second aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier or excipient.
  • a third aspect of the invention is a compound of the invention for use in therapy.
  • a fourth aspect of the invention is the use of a compound of the invention in the manufacture of a medicament for the . treatment of a disease in which a CRTH2 antagonist can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.
  • a fifth aspect of the invention is a method for treating a disease in a patient in which a CRTH2 antagonist can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the patient a therapeutically effective amount of a compound of the invention.
  • compounds with which the invention is concerned are useful in the treatment of disease associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.
  • PGD2 prostaglandin D2
  • diseases include asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer ' s lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneurophathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behget's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel infections,
  • the compounds with which the invention is concerned are primarily of value for the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis.
  • Psoriasis, atopic and non-atopic dermatitis Crohn's disease, ulcerative colitis, and irritable bowel disease are other specific conditions where.the present compounds may have particular utility.
  • salt includes base addition, acid addition and quaternary salts.
  • Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl pipe
  • Specific salts with bases include the benzathine, calcium, diolamine, meglumine, olamine, potassium, procaine, sodium, tromethamine and zinc salts.
  • Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g.
  • acceptable counter-ions may be, for example, chlorides, bromides, sulfates, methanesulfonates, benzenesulfonates, toluenesulfonates (tosylates), napadisylates (naphthalene- 1 ,5-disulfonates or naphthalene-1 -(sulfonic acid)-5-sulfonates), edisylates (ethane-1 ,2-disulfonates or ethane-1 -(sulfonic acid)-2-sulfonates), isethionates (2-hydroxyethylsulfonates), phosphates, acetates, citrates, lactates, tartrates, mesylates, maleates, malates, fumarates, succinates, xinafoates, p- acetamidobenzoates and the like; where
  • prodrugs such as esters
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I).
  • metabolic means e.g. by hydrolysis, reduction or oxidation
  • an ester prodrug of a compound of formula (I) may be convertible by hydrolysis in vivo to the parent molecule.
  • esters of compounds of formula (I) are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonat.es, p-toluene- sulphonates, cyclohexylsulphamates and quinates.
  • ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res., 1987, 18, 379. As used in herein, references to the compounds of formula (I) are meant to also include the prodrug forms.
  • the compounds with which the invention is concerned are CRTH2 receptor antagonists, and are useful in the treatment of diseases which benefit from such modulation.
  • diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavourin ⁇ or colourin ⁇ a ⁇ ents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • almond oil fractionated coconut oil
  • oily esters such as gly
  • the drug may be made up into a cream, lotion or ointment.
  • Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
  • the drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers.
  • the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
  • the active ingredient may also be administered parenterally in a sterile medium.
  • the drug can either be suspended or dissolved in the vehicle.
  • adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • compositions for preventing and treating PGD 2 -mediated diseases comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents.
  • Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: (1) corticosteroids, such as fluticasone, budesonide or ciclesonide; (2) ⁇ 2-adrenoreceptor agonists, such as salmeterol, formeterol or indacaterol; (3) leukotriene modulators, for example leukotriene antagonists such as montelukast or pranlukast or leukotriene biosynthesis inhibitors such as Zileuton or BAY-x1005; (4) anticholinergic agents, for example muscarinic-3 (M 3 ) receptor antagonists such as tiotropium bromide; (5) phosphodiesterase-IV (PDE-IV) inhibitors, such as roflumilast or cilomilast; (6) antihistamines, for example selective histamine-1 (H1) receptor antagonists, such as loratidine or astemizole; (7) antitussive agents, such as codeine
  • the weight ratio of the compound of the invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
  • Mass Spectrometry (LCMS) experiments to determine retention times and associated mass ions were performed using the following methods: Method A: experiments were performed on a Micromass Platform LCT spectrometer with positive ion electrospray and single wavelength UV 254 nm detection using a Higgins Clipeus C18 5 ⁇ m 100 x 3.0 mm column and a 2 ml_ / minute flow rate.
  • the initial solvent system was 95 % water containing 0.1 % formic acid (solvent A) and 5 % acetonitrile containing 0.1 % formic acid (solvent B) for the first minute followed by a gradient up to 5 % solvent A and 95 % solvent B over the next 14 minutes.
  • the final solvent system was held constant for a further 2 minutes.
  • Method B experiments were performed on a Micromass Platform LC spectrometer with positive and negative ion electrospray and ELS / Diode array detection using a Phenomenex Luna C18(2) 3O x 4.6 mm column and a 2 mL / minute flow rate.
  • the solvent system was 95 % solvent A and 5 % solvent B for the first 0.50 minutes followed by a gradient up to 5 % solvent A and 95 % solvent B over the next 4 minutes. The final solvent system was held constant for a further 0.50 minutes
  • Method C experiments were performed on a Agilent Scalar column C18, 5 ⁇ m (4.6 x 50 mm, flow rate 2.5 mL / minute) eluting with a H 2 CVMeCN gradient containing 0.1 % v/v formic acid over 7 minutes with UV detection at 215 and 254 nm.
  • Method D experiments were performed on a Agilent Scalar column C18, 5 ⁇ m (4.6 x 50 mm, flow rate 2.5 mL / minutes) eluting with a H 2 O / MeCN gradient containing 0.1 % v/v NH 4 OH over 7 minutes with UV detection at 215 and 254 nm.
  • Preparation 1e acetic acid acetoxy[4-(morpholine-4-sulfonyl)phenyl]methyl ester
  • a solution of morpholine (0.85 ml_) in dichloromethane (5.0 mL) was added dropwise to a mixture of acetic acid acetoxy(4-chlorosulfonylphenyl)methyl ester (1.0 g) and dichloromethane (25 mL) at 0 0 C and the resulting mixture was stirred at room temperature overnight.
  • the title compound was prepared by the method of Preparation 1g using (7-cyano- 2-methylindolizin-3-yl)acetic acid ethyl ester and 3-chloro-4- ethanesulfonylbenzaldehyde.
  • Example 3 ⁇ 1 -[3-chloro-4-(morpholine-4-sulf onyl)benzyl]-7-cyano-2- methylindolizin-3-yl ⁇ acetic acid
  • the title compound was prepared by the method of Preparation 1g using (7-cyano- 2-methylindolizin-3-yl)acetic acid ethyl ester and 3-chloro-4-(morpholine-4- sulfonyl)benzaldehyde.
  • the title compound was prepared by the method of Preparation 4b using 4-(2- chloro-4-fluorobenzenesulfonyl)morpholine.
  • Preparation 5c ⁇ 1 -[3-chloro-4-(morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2- methylindolizin-3-yl ⁇ acetic acid ethyl ester
  • the title compound was prepared by the method of Preparation 4c using (7-cyano-2- methylindolizin-3-yi)acetic acid ethyl ester and bis(3-chloro-4- morpholinosulfonylbenzene)disulfide.
  • Radioligand Binding Assay The receptor binding assay is performed in a final volume of 200 ⁇ l_ binding buffer [10 mM BES (pH 7.4), 1 mM EDTA, 10 mM manganese chloride, 0.01 % BSA] and 1 nM [ 3 H]-PGD 2 (Amersham Biosciences UK Ltd). Ligands are added in assay buffer containing a constant amount of DMSO (1 % by volume). Total binding is determined using 1 % by volume of DMSO in assay buffer and non-specific binding is determined using 10 ⁇ M of unlabeled PGD 2 (Sigma).
  • HEK Human embryonic kidney
  • HEK cell membranes 3.5 ⁇ g expressing the CRTH2 receptor are incubated with 1.5 mg wheatgerm agglutinin SPA beads and 1 nM [ 3 H]-PGD 2 (Amersham Biosciences UK Ltd) and the mixture incubated for 3 hours at room temperature.
  • Bound [ 3 H]-PGD 2 is detected using a Microbeta TRILUX liquid scintillation counter (Perkin Elmer).
  • Compound IC 50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC 50 calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation.
  • the GTP ⁇ S Assay is performed in a final volume of 200 mL assay buffer (2OmM HEPES pH 7.4, 1OmM MgCI 2 , 10OmM NaCI, 10 ⁇ g/mL saponin). DMSO concentrations are kept constant at 1% by volume.
  • Human embryonic kidney (HEK) cell membranes (3.5 ⁇ g) expressing the CRTH2 receptor are incubated with the compounds for 15 min at 30° C prior to addition of PGD 2 (3OnM final concentration) and GTP (10 ⁇ M final concentration).
  • the assay solutions are then incubated for 30 minutes at 30° C, followed by addition of [ 35 S]-GTP ⁇ S (0.1 nM final concentration).
  • the assay plate is than shaken and incubated for 5 minutes at 30°C.
  • SPA beads (Amersham Biosciences, UK) are added to a final concentration of 1.5mg/well and the plate shaken and incubated for 30 minute at 30° C.
  • the sealed plate is centrifuged at 1000g for IOmins at 30oC and the bound [ 35 S]-GTP ⁇ S is detected on Microbeta scintillation counter (Perkin Elmer).
  • Compound IC 50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC 50 calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation.
  • the compounds of the Examples above were tested in the CRTH2 radioligand binding and GTP ⁇ S functional assays described above; the compounds all have IC 50 values of less than 1 ⁇ M in both assays.
  • the compound of Example 1 had an IC 50 value of 58 nM in the CRTH2 radioligand binding assay, and the compound of Example 6 had an IC 50 value of 19 nM in that assay..

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The specific compounds of this list : {7-cyano-2-methyl-1-[4-(morpholine-4-sutfonyl)benzyl]indolizin-3-yl}acetic acid, {1 -(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro-4-(morpholine-4-sutfonyl)phenylsutfanyl]-7-cyano-2-methylindolizin-3- yl}acetic acid, {7-cyano-1 -(6-fluoroquinolin-2-y1methyl)-2-methylindolizin-3-yl}acetic acid are ligands of the CRTH2 receptor and are useful in the treatment of respiratory diseases.

Description

INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS
This invention relates to specific indolizine compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), and their use in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component.
Background to the Invention Mast cells are known to play an important role in allergic and immune responses through the release of a number of mediators, such as histamine, leukotrienes, cytokines, prostaglandin D2, etc (Boyce; Allergy Asthma Proc, 2004, 25, 27-30). Prostaglandin D2 (PGD2) is the major metabolite produced by the action of cyclooxygenase on arachadonic acid by mast cells in response to allergen challenge (Lewis et al; J. Immunol., 1982, 129, 1627-1631). It has been shown that PGD2 production is increased in patients with systemic mastocytosis (Roberts; N. Engl. J. Med., 1980, 303, 1400-1404), allergic rhinitis (Naclerio et al; Am. Rev. Respir. Dis., 1983, 128, 597-602; Brown et al; Arch. Otolarynol. Head Neck Surg., 1987, 113, 179-183; Lebel et al; J. Allergy Clin. Immunol., 1988, 82, 869-877), bronchial asthma (Murray et al; N. Engl. J. Med., 1986, 315, 800-804; Liu et al; Am. Rev. Respir. Dis., 1990, 142, 126-132; Wenzel et al; J. Allergy Clin. Immunol., 1991 , 87, 540-548), and urticaria (Heavey et al; J. Allergy Clin. Immunol., 1986, 78, 458-461). PGD2 mediates it effects through two receptors, the PGD2 (or DP) receptor (Boie et al; J. Biol. Chem., 1995, 270, 18910-18916) and the chemoattractant receptor- homologous molecule expressed on Th2 (or CRTH2) (Nagata et al; J. Immunol., 1999, 162, 1278-1289; Powell; Prostaglandins Luekot. Essent. Fatty Acids, 2003, 69, 179-185). Therefore, it has been postulated that agents that antagonise the effects of PGD2 at its receptors may have beneficial effects in a number of disease states.
The CRTH2 receptor has been shown to be expressed on cell types associated with allergic inflammation, such as basophils, eosinophils, and Th2-type immune helper cells (Hirai et al; J. Exp. Med., 2001 , 193, 255-261). The CRTH2 receptor has been shown to mediate PGD2-mediated cell migration in these cell types (Hirai et al; J. Exp. Med., 2001 , 193, 255-261), and also to play a major role in neutrophil and eosinophil cell recruitment in a model of contact dermatitis (Takeshita et al; Int. Immunol., 2004, 16, 947-959). Ramatroban {(3R)-3-[(4-fluorophenyl)sulphonyl- amino]- 1 ,2,3,4-tetrahydro-9H-carba2ole-9-propanoic acid}, a dual CRTH2 and thromboxane A2 receptor antagonist, has been shown to attenuate these responses (Sugimoto et al; J. Pharmacol. Exp. Ther., 2003, 305, 347-352; Takeshita et al; op. cit). The potential of PGD2 both to enhance allergic inflammation and induce an inflammatory response has been demonstrated in mice and rats. Transgenic mice over expressing PGD2 synthase exhibit an enhanced pulmonary eosinophilia and increased levels of Th2 cytokines in response to allergen challenge (Fujitani et al; J. Immunol., 2002, 168, 443-449). In addition, exogenously administered CRTH2 agonists enhance the allergic response in sensitised mice (Spik et al; J. Immunol., 2005, 174, 3703-3708). In rats exogenously applied CRTH2 agonists cause a pulmonary eosinophilia but a DP agonist (BW 245C) or a TP agonist (I-BOP) showed no effect (Shirashi et al; J. Pharmacol. Exp Ther, 2005, 312, 954-960). These observations suggest that CRTH2 antagonists may have valuable properties for the treatment of diseases mediated by PGD2.
Our copending application PCT/GB2006/003394 relates to CRTH2 antagonist compounds of formula (I) and salts, N-oxides, hydrates and solvates thereof:
Figure imgf000003_0001
wherein
R1, R2, R3 and R4 each independently are hydrogen, CrC6alkyl, fully or partially fluorinated CrC6alkyl, halo, -S(O)nR10, -SO2N(R10)2, -N(R10)2, -C(O)N(R10)2, - NR10C(O)R9, -CO2R10, -C(O)R9, -NO2, -CN Or -OR11; wherein each R9 is independently d-C'βalkyl, aryl, heteroaryl;
R10 is independently hydrogen, CrC6alkyl, aryl, or heteroaryl;
Ri1 is hydrogen, CrC6alkyl, fully or partially fluorinated C|-C6alkyl or a group
-SO2R10; n is 0, 1 or 2;
R5 is CrC6alkyl, fully or partially fluorinated CrC6alkyl, Ci-C6alkenyl, CrC6alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is hydrogen, CrC6alkyl or fully or partially fluorinated d-C6alkyl; R7 and R8 are independently hydrogen or Ci-C6alkyl, or R7 and R8 together with the atom to which they are attached form a cycloalkyl group; and X is -CHR6-, -S(O)n-, -C(O)-, -NR6SO2- or -SO2NR6- wherein n is 0, 1 or 2.
Detailed Description of the Invention
The present invention provides a group of specific compounds falling within the scope of, but not specifically disclosed in our copending application PCT/GB2006/003394 referred to above.
The invention provides a compound selected from the group consisting of
{7-cyano-2-methyl-1-[4-(morpholine-4-sulfonyl)benzyl]indolizin-3-yl}acetic acid,
[1 -(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl]acetic acid,
{1-[3-chloro-4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid,
[1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl]acetic acid,
{1-[3-chloro-4-(morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2-methylindolizin-3- yl}acetic acid,
[7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl]acetic acid,
and salts, N-oxides, hydrates and solvates thereof.
Compounds with which the invention is concerned are CRTH2 receptor antagonists.
A second aspect of the invention is a pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier or excipient.
A third aspect of the invention is a compound of the invention for use in therapy. A fourth aspect of the invention is the use of a compound of the invention in the manufacture of a medicament for the . treatment of a disease in which a CRTH2 antagonist can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.
A fifth aspect of the invention is a method for treating a disease in a patient in which a CRTH2 antagonist can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the patient a therapeutically effective amount of a compound of the invention.
In particular, compounds with which the invention is concerned are useful in the treatment of disease associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.
Examples of such diseases include asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneurophathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behget's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodossa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophil fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.
However, the compounds with which the invention is concerned are primarily of value for the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis. Psoriasis, atopic and non-atopic dermatitis Crohn's disease, ulcerative colitis, and irritable bowel disease are other specific conditions where.the present compounds may have particular utility.
As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Specific salts with bases include the benzathine, calcium, diolamine, meglumine, olamine, potassium, procaine, sodium, tromethamine and zinc salts. Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p- toluenesulphonic, benzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like. Where a compound contains a quaternary ammonium group acceptable counter-ions may be, for example, chlorides, bromides, sulfates, methanesulfonates, benzenesulfonates, toluenesulfonates (tosylates), napadisylates (naphthalene- 1 ,5-disulfonates or naphthalene-1 -(sulfonic acid)-5-sulfonates), edisylates (ethane-1 ,2-disulfonates or ethane-1 -(sulfonic acid)-2-sulfonates), isethionates (2-hydroxyethylsulfonates), phosphates, acetates, citrates, lactates, tartrates, mesylates, maleates, malates, fumarates, succinates, xinafoates, p- acetamidobenzoates and the like; wherein the number of quaternary ammonium species balances the pharmaceutically acceptable salt such that the compound has no net charge.
Use of prodrugs, such as esters, of compounds with which the invention is concerned is also part of the invention. "Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I). For example an ester prodrug of a compound of formula (I) may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of formula (I) are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-β-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonat.es, p-toluene- sulphonates, cyclohexylsulphamates and quinates. Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res., 1987, 18, 379. As used in herein, references to the compounds of formula (I) are meant to also include the prodrug forms.
Compositions
As mentioned above, the compounds with which the invention is concerned are CRTH2 receptor antagonists, and are useful in the treatment of diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. Orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavourinα or colourinα aαents.
For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
The drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers. For delivery by inhalation, the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
Other compounds may be combined with compounds of this invention for the prevention and treatment of prostaglandin-mediated diseases. Thus the present invention is also concerned with pharmaceutical compositions for preventing and treating PGD2-mediated diseases comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents. Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: (1) corticosteroids, such as fluticasone, budesonide or ciclesonide; (2) β2-adrenoreceptor agonists, such as salmeterol, formeterol or indacaterol; (3) leukotriene modulators, for example leukotriene antagonists such as montelukast or pranlukast or leukotriene biosynthesis inhibitors such as Zileuton or BAY-x1005; (4) anticholinergic agents, for example muscarinic-3 (M3) receptor antagonists such as tiotropium bromide; (5) phosphodiesterase-IV (PDE-IV) inhibitors, such as roflumilast or cilomilast; (6) antihistamines, for example selective histamine-1 (H1) receptor antagonists, such as loratidine or astemizole; (7) antitussive agents, such as codeine or dextramorphan; (8) non-selective COX-1 / COX-2 inhibitors, such as ibuprofen or ketoprofen; (9) COX-2 inhibitors, such as celecoxib and rofecoxib; (10) VLA-4 antagonists, such as those described in WO97/03094 and WO97/02289; (11) TNF-α inhibitors, for example anti-TNF monoclonal antibodies, such as Remicade and CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel; (12) inhibitors of matrix metalloprotease (MMP), for example MMP8, 9 and 12; (13) human neutrophil elastase inhibitors, such as those described in WO2005/026124 and WO2003/053930; (14) Adenosine A2a agonists such as those described in EP1052264 and EP1241176 (15) Adenosine A2b antagonists such as those described in WO2002/42298; (16) modulators of chemokine receptor function, for example antagonists of CCR3 and CCR8; (17) compounds which modulate the action of other prostanoid receptors, for example a PGD2 (DP) receptor antagonist or a thromboxane A2 antagonist; and (18) compounds which modulate Th2 function, for example, PPAR agonists.
The weight ratio of the compound of the invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
The following examples describe the preparation of compounds of the invention:
Examples
1H NMR spectra were recorded at ambient temperature using a Varian Unity Inova (400MHz) spectrometer with a triple resonance 5 mm probe spectrometer. Chemical shifts are expressed in ppm relative to tetramethylsilane. The following abbreviations have been used: br s = broad singlet, s = singlet, d = doublet, dd = double doublet, t = triplet, q = quartet, m = multiplet.
Mass Spectrometry (LCMS) experiments to determine retention times and associated mass ions were performed using the following methods: Method A: experiments were performed on a Micromass Platform LCT spectrometer with positive ion electrospray and single wavelength UV 254 nm detection using a Higgins Clipeus C18 5 μm 100 x 3.0 mm column and a 2 ml_ / minute flow rate. The initial solvent system was 95 % water containing 0.1 % formic acid (solvent A) and 5 % acetonitrile containing 0.1 % formic acid (solvent B) for the first minute followed by a gradient up to 5 % solvent A and 95 % solvent B over the next 14 minutes. The final solvent system was held constant for a further 2 minutes.
Method B: experiments were performed on a Micromass Platform LC spectrometer with positive and negative ion electrospray and ELS / Diode array detection using a Phenomenex Luna C18(2) 3O x 4.6 mm column and a 2 mL / minute flow rate. The solvent system was 95 % solvent A and 5 % solvent B for the first 0.50 minutes followed by a gradient up to 5 % solvent A and 95 % solvent B over the next 4 minutes. The final solvent system was held constant for a further 0.50 minutes
Method C: experiments were performed on a Agilent Scalar column C18, 5 μm (4.6 x 50 mm, flow rate 2.5 mL / minute) eluting with a H2CVMeCN gradient containing 0.1 % v/v formic acid over 7 minutes with UV detection at 215 and 254 nm. Gradient information: 0.0-0.1 minutes: 95 % H2O / 5 % MeCN; 0.1-5.0 minutes; Ramp from 95 % H2O / 5 % MeCN to 5 % H2O / 95 % MeCN; 5.0-5.5 minutes: Hold at 5 % H2O / 95 % MeCN; 5.5-5.6 minutes: Hold at 5 % H2O / 95 % MeCN, flow rate increased to 3.5 mL / minutes; 5.6-6.6 minutes: Hold at 5 % H2O / 95 % MeCN, flow rate 3.5 mL / minutes; 6.6-6.75 minutes: Return to 95 % H2O / 5 % MeCN, flow rate 3.5 mL / minutes; 6.75-6.9 minutes: Hold at 95 % H2O / 5 % MeCN, flow rate 3.5 mL / minutes; 6.9-7.0 minutes: Hold at 95 % H2O minutes 5 % MeCN, flow rate reduced to 2.5 mL / minutes Mass spectra were obtained using an electrospray ionization source in either the positive or negative mode.
Method D: experiments were performed on a Agilent Scalar column C18, 5 μm (4.6 x 50 mm, flow rate 2.5 mL / minutes) eluting with a H2O / MeCN gradient containing 0.1 % v/v NH4OH over 7 minutes with UV detection at 215 and 254 nm. Gradient information: 0.0-0.1 min: 95 % H2O / 5 % MeCN; 0.1-5.0 minutes; Ramp from 95 % H2O / 5 % MeCN to 5 % H2O / 95 % MeCN; 5.0-5.5 minutes: Hold at 5 % H2O / 95 % MeCN; 5.5-5.6 minutes: Hold at 5 % H2O / 95 % MeCN, flow rate increased to 3.5 mL / minutes; 5.6-6.6 minutes: Hold at 5 % H2O / 95 % MeCN, flow rate 3.5 mL / minutes; 6.6-6.75 minutes: Return to 95 % H2O / 5 % MeCN, flow rate 3.5 mL / minutes; 6.75-6.9 minutes: Hold at 95 % H2O / 5 % MeCN, flow rate 3.5 ml_ / minutes; 6.9-7.0 minutes: Hold at 95 % H2O / 5 % MeCN, flow rate reduced to 2.5 mL / minutes Mass spectra were obtained using an electrospray ionization source in either the positive or negative mode.
Example 1 : {7-cyano-2-methyl-1-[4-(morpholine-4-sulfonyl)benzyl]indolizin-3- yl}acetic acid
Figure imgf000011_0001
Preparation 1 a: 2-methylisonicotinonitrile
A mixture of 2-chloroisonicotinonitrile (28 g), tetrakis(triphenylphosphine)palladium(0) (5.0 g), trimethylaluminium (2.0 M in hexanes, 110 mL) and 1 ,4-dioxane (400 mL) was heated at reflux for 2 hours. The mixture was cooled to room temperature, diluted with 1.0 M aqueous hydrochloric acid and the organic phase extracted with 1.0 M aqueous hydrochloric acid. The combined aqueous phases were washed with diethyl ether, basified by the addition of concentrated aqueous sodium hydroxide solution and then extracted with diethyl ether. The combined extracts were dried over magnesium sulfate and the solvent removed under reduced pressure to afford title compound, 24 g.
1H NMR (CDCI3): δ 2.65 (s, 3H), 7.35 (m, 1 H), 7.40 (br s, 1H), 8.70 (d, J = 5.0 Hz, 1 H).
Preparation 1b: 2-methylindolizine-7-carbonitrile
A mixture of 2-methylisonicotinonitrile (4.0 g), 1 -bromopropan-2-one (9.3 g), sodium hydrogen carbonate (6.8 g) and acetonitrile (40 mL) was heated at reflux for 14 hours. The mixture was cooled to room temperature, diluted with water and extracted with ethyl acetate. The combined extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and the solvent removed under reduced pressure. Purification of the residue by column chromatography on silica gel, eluting with a mixture of cyclohexane and ethyl acetate gave title compound as a yellow solid, 1.5 g.
1H NMR (CDCI3): δ 2.35 (s, 3H), 6.50 (dd, J = 1.6, 7.2 Hz, 1 H), 6.55 (br S, 1 H), 7.25 (br s, 1 H), 7.70 (br s, 1 H), 7.80 (m, 1 H).
Preparation 1 c: (7-cyano-2-methylindolizin-3-yl)acetic acid ethyl ester
A solution of ethyl diazoacetate (5.4 ml_) in toluene (40 ml_) was added portionwise to a mixture of 2-methylindolizine-7-carbonitrile (8.1 g), copper bronze (3.3 g) and toluene (200 ml_) at reflux. The resulting mixture was heated at reflux for 2 hours, cooled to room temperature and then filtered. The filtrate was concentrate under reduced pressure and the residue purified by column chromatography on silica gel, eluting with a mixture of pentane and dichloromethane (9:1 to 0:1 by volume) to afford title compound, 5.7 g.
1H NMR (CDCI3): δ 1.25 (t, J = 7.1 Hz, 3H), 2.35 (s, 3H), 3.90 (s, 2H)1 4.15 (q, J = 7.1 Hz, 2H), 6.55 (m, 1H), 6.60 (d, J = 1.7 Hz, 1 H), 7.70 (br S, 1 H), 7.85 (d, J = 7.1 Hz, 1 H).
Preparation 1d: acetic acid acetoxy(4-chlorosulfonylphenyl)methyl ester
Sulfuric acid (56 g) was added dropwise to a mixture of 4-methylbenzenesulfonyl chloride (45 g), acetic acid (375 mL) and acetic anhydride (375 mL) at 0 0C and the resulting mixture was treated portionwise with chromium(VI) oxide (66 g). The mixture was stirred at room temperature for 30 minutes, poured into ice/water and the solid collected by filtration. The solid was dissolved in dichloromethane, dried over magnesium sulfate and concentrated under reduced pressure. The residue was crystallised from a mixture of acetone and hexane to afford title compound.
1H NMR (CDCI3): δ 2.15 (s, 6H), 7.75 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H).
Preparation 1e: acetic acid acetoxy[4-(morpholine-4-sulfonyl)phenyl]methyl ester A solution of morpholine (0.85 ml_) in dichloromethane (5.0 mL) was added dropwise to a mixture of acetic acid acetoxy(4-chlorosulfonylphenyl)methyl ester (1.0 g) and dichloromethane (25 mL) at 0 0C and the resulting mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure and the residue purified by column chromatography on silica gel, eluting with a mixture of cyclohexane and ethyl acetate (8:1 by volume) to afford title compound, 0.70 g.
1H NMR (CDCI3): δ 2.15 (s, 6H), 3.05 (m, 4H) 3.75 (m, 4H), 7.80 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H), 8.05 (d, J = 8.6 Hz, 2H).
Preparation 1f: 4-(morpholine-4-sulfonyl)benzaldehyde
A mixture of acetic acid acetoxy[4-(morpholine-4-sulfonyl)phenyl]methyI ester (0.70 g), water (25 mL), industrial methylated spirits (25 mL) and sodium carbonate (0.83 g) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure and the residue treated with glacial acetic acid. The resulting precipitate was collected by filtration and dried to afford title compound, 0.48 g.
1H NMR (CDCI3): δ 3.05 (m, 4H), 3.75 (m, 4H), 7.90 (d, J = 8.6 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 10.15 (S, 1H).
Preparation 1g: {7-cyano-2-methyl-1-[4-(morpholine-4-sulfonyl)benzyl]indolizin-3- yl}acetic acid ethyl ester
A mixture of (7-cyano-2-methylindolizin-3-yl)acetic acid ethyl ester (0.46 g), 4- (morpholine-4-sulfonyl)benzaldehyde (0.48 g) and 1 ,2-dichloroethane (15 mL) at 0 0C was treated dropwise with triethylsilane (1.5 mL) followed by trifluoroacetic acid (4.2 mL) and the resulting mixture was stirred at room temperature overnight. The mixture was washed with saturated aqueous sodium hydrogen carbonate solution, dried over sodium sulfate and the solvent removed under reduced pressure. The residue was purified by column chromatography on silica gel to afford title compound, 0.18 g.
1H NMR (CDCI3): δ 1.25 (t, J = 7.3 Hz, 3H), 2.20 (s, 3H), 2.95 (m, 4H), 3.70 (m, 4H), 3.90 (s, 2H), 4.15 (q, J = 7.3 Hz, 2H), 4.20 (s, 2H), 6.60 (dd, J = 1.7, 7.3 Hz, 1 H), 7.25 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.70 (dd, J = 0.9, 1.7 Hz, 1 H), 7.85 (dd, J = 0.9, 7.3 Hz, 1H).
Preparation 1 h: {7-cyano-2-methyl-1 -[4-(morpholine-4-sulfonyI)benzyl]indolizin-3- yljacetic acid
A solution of {7-cyano-2-methyl-1-[4-(morpholine-4-sulfonyl)benzyl]indolizin-3- yl}acetic acid ethyl ester (0.18 g) in tetrahydrofuran (10 mL) was treated with a solution of lithium hydroxide (0.050 g) in water (10 mL) and the resulting mixture was stirred at room temperature for 1 hour. The mixture was acidified by the addition 1.0 M aqueous hydrochloric acid, extracted with ethyl acetate and the combined extracts dried over sodium sulfate. The solvent was removed under reduced pressure to afford title compound as a yellow solid, 0.059 g.
1H NMR (CD3OD): δ 2.15 (s, 3H), 2.85 (m, 4H), 3.60 (m, 4H), 3.95 (s, 2H), 4.25 (s, 2H), 6.60 (dd, J = 1.6, 7.0 Hz, 1 H), 7.35 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.90 (dd, J = 0.7, 1.6 Hz, 1 H), 8.00 (dd, J = 0.7, 7.0 Hz, 1 H). MS: ESI (+ve) (Method A): 454 (M+H)+, Retention time 9.7 min.
Example 2: [i-β-chloro^-ethanesulfonylbenzylJ-T-cyano^-methylindolizin-S- yl]acetic acid
Figure imgf000014_0001
Preparation 2a: 3-chIoro-4-ethylsulfanylbenzaldehyde
A solution of 3-chloro-4-fluorobenzaldehyde (5.0 g) in Λ/,Λ/-dimethylformamide (10 mL) was treated with sodium ethanethiolate (2.7g) and the resulting mixture was stirred at 70 0C for 7 hours and then at room temperature overnight. The mixture was partitioned between water (30 mL) and diethyl ether (30 mL) and the aqueous phase extracted with diethyl ether (20 mL). The combined organic phases were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and the solvent removed under reduced pressure. Purification of the residue by column chromatography on silica gel, eluting with a mixture of /so-hexane and ethyl acetate (1 :9 by volume) gave title compound as a yellow oil, 5.0 g.
Preparation 2b: 3-chloro-4-ethanesulfonylbenzaldehyde
A solution of 3-chloro-4-ethylsulfanylbenzaldehyde (5.0 g) in dichloromethane (25 mL) at 0 0C was treated with 3-chloroperoxybenzoic acid (8.6 g) and the resulting mixture was stirred at room temperature for 2 hours. The mixture was diluted with saturated aqueous sodium hydrogen carbonate solution and the organic phase was washed with saturated aqueous sodium sulfite solution and water. The pH of the combined aqueous phases was adjusted to 6 and then extracted with dichloromethane, ethyl acetate and chloroform. The combined organic phases were dried over magnesium sulfate and the solvent removed under reduced pressure. Purification of the residue by column chromatography on silica gel, eluting with a mixture of ethyl acetate and /so-hexane (1:9 to 3:7 by volume) gave title compound, 0.60 g.
1H NMR (CDCI3): δ 1.30 (t, 3H), 3.50 (q, 2H), 8.0 (dd, 1H), 8.05 (d, 1H), 8.30 (d, 1 H), 10.10 (s, 1 H).
Preparation 2c: [1 -(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3- yl]acetic acid ethyl ester
The title compound was prepared by the method of Preparation 1g using (7-cyano- 2-methylindolizin-3-yl)acetic acid ethyl ester and 3-chloro-4- ethanesulfonylbenzaldehyde.
1H NMR (DMSO-d6): δ 1,10 (t, 3H), 1.15 (t, 3H), 2.10 (s, 3H), 3.45 (q, 2H)1 4.05 (q, 2H), 4.10 (s, 2H), 4.30 (s, 1 H), 6.75 (dd, 1 H), 7.35 (dd, 1H), 7.50 (d, 1 H), 7.90 (d, 1H), 8.15 (d, 1 H), 8.30 (s, 1 H). MS: ESI (+ve) (Method D): 459 (M+H)+, Retention time 4.2 mm.
Preparation 2d: [1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3- yl]acetic acid A mixture of [i-β-chloro^-ethanesulfonylbenzyl^-cyano^-methylindolizin-S- yljacetic acid ethyl ester. (0.025 g), ethanol (0.5 mL) and tetrahydrofuran (0.3 mL) was treated with 1.0 M aqueous lithium hydroxide solution (0.14 mL) and the resulting mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, diluted with water and the pH adjusted to 4 by the addition of glacial acetic acid. The mixture was extracted with dichloromethane and the combined extracts were dried over magnesium sulfate and then concentrated under reduced pressure to afford title compound as a green solid, 0.020 g.
1H NMR (DMSO-d6): δ 1.10 (t, 3H), 2.10 (s,.3H), 3.45 (q, 2H), 4.00 (s, 2H), 4.25 (s, 1 H), 6.75 (dd, 1 H), 7.35 (dd, 1 H), 7.55 (d, 1 H), 7.90 (d, 1 H), 8.10 (d, 1H), 8.30 (s, 1 H). MS: ESI (+ve) (Method C): 431 (M+H)\ Retention time 3.1 min.
Example 3: {1 -[3-chloro-4-(morpholine-4-sulf onyl)benzyl]-7-cyano-2- methylindolizin-3-yl}acetic acid
Figure imgf000016_0001
Preparation 3a: 3-chloro-4-(morpholine-4-sulfoηyl)benzonitrile
A solution of 2-chloro-4-cyanobenzenesulfonyl chloride (5.0 g) in dichloromethane (20 mL) at 0 0C was treated with morpholine (3.7 mL) and the resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with dichloromethane, washed with 10 % aqueous hydrochloric acid, dilute aqueous sodium hydrogen carbonate solution and water and then dried over magnesium sulfate. The solvent was removed under reduced pressure to title compound, 5.5 g.
1H NMR (CDCi3): δ 3.35 (dd, 4H), 3.75 (dd, 4H), 7.70 (dd, 1 H), 7.85 (d, 1H), 8.15 (d, 1 H). Preparation 3b: 3-chloro-4-(morpholine-4-sulfonyl)benzaldehyde
A solution of 3-chloro-4-(morpholine-4-sulfonyl)benzonitrile (5.5 g) in dichloromethane (20 ml_) at -75 0C was treated with diisobutylaluminium hydride (1.0
M solution in dichloromethane, 19 ml_) and the resulting mixture was stirred at -78
0C for 1 hour. The mixture was treated with 1.0 M aqueous hydrochloric acid and extracted with dichloromethane. The combined extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel, eluting with a mixture of ethyl acetate and /so-hexane (1 :9 to 1 :2 by volume) gave title compound, 1.3 g.
1H NMR (DMSO-d6): δ 3.20-3.25 (m, 4H), 3.60-3.65 (m, 4H), 8.05 (dd, 1H), 8.15- 8.20 (m, 2H), 10.10 (s, 1H).
MS: ESI (+ve) (Method D): 290 (M+H)+, Retention time 4.0 min.
Preparation 3c: {1 -[3-chloro-4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2- methylindolizin-3-yl}acetic acid ethyl ester
The title compound was prepared by the method of Preparation 1g using (7-cyano- 2-methylindolizin-3-yl)acetic acid ethyl ester and 3-chloro-4-(morpholine-4- sulfonyl)benzaldehyde.
1H NMR (DMSO-d6): δ 1.10 (t, 3H), 2.10 (s, 3H), 3.10-3.15 (m, 4H), 3.55-3.60 (m, 4H), 4.05 (q, 2H), 4.10 (s, 2H), 4.25 (s, 1H), 6.75 (dd, 1H), 7.30 (dd, 1H), 7.50 (d, 1H), 7.85 (d, 1H), 8.15 (dd, 1H), 8.30 (s, 1 H). MS: ESI (+ve) (Method D): 516 (M+H)+, Retention time 4.3 min.
Preparation 3d: {1-[3-chloro-4-(morpholine-4-sulfonyI)benzyl]-7-cyano-2- methyIindolizin-3-yl}acetic acid
The title compound was prepared by the method of Preparation 2d using {1-[3- chloro-4-(morpholine-4-sulfonyi)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid ethyl ester. 1H NMR (DMSO-d6): δ 2.10 (s, 3H), 3.10-3.15 (m, 4H), 3.55-3.60 (m, 4H), 4.00 (s, 2H), 4.25 (s, 2H), 6.75 (dd, 1 H), 7.30 (dd, 1H), 7.50 (d, 1 H), 7.85 (d, 1H), 8.15 (d, 1 H), 8.30 (s, 1H). MS: ESI (+ve) (Method C): 488 (M+H)+, Retention time 3.2 min
Example 4: [1 -(3-chloro-4-ethanesulf onylphenvlsulf anyl)-7-cyano-2- methylindolizin-3-yl]acetic acid
Figure imgf000018_0001
Preparation 4a: 2-chloro-1-ethanesulfonyl-4-fluorobenzene
2-Chloro-4-fluorobenzenesulfonyl chloride (3.8 g) was added portionwise over a period of 1 hour to a solution of sodium bicarbonate (2.8 g) and sodium sulfite (4.0 g) in water (80 ml_) at 75 0C and the resulting mixture was heated at 75 0C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with Λ/,Λ/-dimethylformamide (30 mL), sodium bicarbonate (2.8 g) and ethyl iodide (1.3 mL) and the resulting mixture heated at 75 0C for 2 hours and then cooled to room temperature and diluted with water (250 mL) and ethyl acetate (200 mL). The organic phase was dried over magnesium sulfate and the solvent removed under reduced pressure. Purification of the residue by column chromatography on silica gel, eluting with a mixture of ethyl acetate and iso- hexane (1:4 by volume) gave title compound, 2.1 g.
1H NMR (CDCI3): δ 1.25 (t, 3H), 3.40 (q, 2H), 7.20 (ddd, 1 H), 7.30 (dd, 1H), 8.15 (dd, 1 H).
Preparation 4b: bis(3-chloro-4-ethanesulfonylbenzene)disulfide
A mixture of 2-chloro-1-ethanesulfonyl-4-fluorobenzene (1.8 g), sodium hydrogen sulfide (4.1 g) and 1-methylpyrrolidin-2-one (5.0 mL) was stirred at 80 0C for 1 hour and then at room temperature for 1 hour. The mixture was diluted with water, filtered and the pH of the filtrate adjusted to 1 by the addition of concentrated hydrochloric acid. The mixture was decanted and residual gum washed and decanted a further 3 times with water. The residue was partitioned between dichloromethane and water and the organic phase was washed with water, dried over magnesium sulfate and the solvent removed under reduced pressure to afford title compound, 1.4 g.
MS: ESI (+ve) (Method C): 471 (M+H)+, Retention time 4.2 min.
Preparation 4c: [1 -(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2- methylindolizin-3-yI]acetic acid ethyl ester
Sulfuryl chloride (0.036 ml_) was added to a solution of bis(3-chloro-4- ethanesulfonylbenzene)disulfide (0.30 g) in dichloromethane (5.0 ml.) at 0 0C and the resulting mixture was stirred at this temperature for 15 minutes and then at room temperature for 1.5 hours This mixture was then added dropwise to a solution of (J- cyano-2-methylindolizin-3-yl)acetic acid ethyl ester (0.15 g) in dichloromethane (2.0 mL) at room temperature and the resulting mixture was stirred at this temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and dried over magnesium sulfate. The solvent was removed under reduced pressure and the residue purified by column chromatography on silica gel, eluting with a mixture of ethyl acetate, diethyl ether and /so-hexane (1:4:12 by volume) to give title compound, 0.060 g.
1H NMR (DMSO-d6): δ 1.10 (t, 3H), 1.20 (t, 3H), 2.20 (s, 3H), 3.40 (q, 2H), 4.10 (q, 2H), 4.25 (s, 2H), 7.05 (dd, 1H), 7.05 (dd, 1 H), 7.20 (d, 1H), 7.80 (d, 1 H), 8.10 (s, 1H), 8.45 (dd, 1 H). MS: ESI (+ve) (Method C): 477 (M+H)+, Retention time 4.2 min
Preparation 4d: [1 -(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2- methylindolizin-3-yl]acetic acid
The title compound was prepared by the method of Preparation 2d using [1-(3- chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl]acetic acid ethyl ester 1H NMR (DMSO-d6): δ 1.10 (t, 3H), 2.20 (s, 3H), 3.40 (q, 2H), 4.15 (s, 2H), 7.00- 7.05 (m, 2H), 7.20 (d, 1 H), 7.80 (d, 1 H), 8.10 (br S, 1 H), 8.40 (d, 1H), 8.45 (dd, 1 H), 12.70 (br s, 1H). MS: ESI (+ve) (Method C): 449 (M+H)+, Retention time 3.4 min.
Example 5: {i-fS-chloro^-tmorpholine-A-sulfonyOphenylsulfanyll-T-cyano-Z- methylindolizin-3-yl}acetic acid
Figure imgf000020_0001
Preparation 5a: 4-(2-chloro-4-fluorobenzenesulfonyl)morpholine
A solution of 2-chloro-4-fluorobenzenesulfonyl chloride (2.0 g) in dichloromethane (20 ml_) at 0 0C was treated with morpholine (1.3 ml_) and the resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with dichloromethane, washed with 10 % aqueous hydrochloric acid, dilute aqueous sodium hydrogen carbonate solution and water and then dried over magnesium sulfate. The solvent was removed under reduced pressure to afford title compound, 2.3 g.
MS: ESI (+VΘ) (Method D): 280 (M+H)+, Retention time 5.2 min.
Preparation 5b: bis(3-chloro-4-morphoIinosulfonylbenzene)disulfide
The title compound was prepared by the method of Preparation 4b using 4-(2- chloro-4-fluorobenzenesulfonyl)morpholine.
Preparation 5c: {1 -[3-chloro-4-(morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2- methylindolizin-3-yl}acetic acid ethyl ester The title compound was prepared by the method of Preparation 4c using (7-cyano-2- methylindolizin-3-yi)acetic acid ethyl ester and bis(3-chloro-4- morpholinosulfonylbenzene)disulfide.
1H NMR (DMSO-d6): δ 1.20 (t, 3H), 2.20 (s, 3H), 3.05-3.10 (m, 4H), 3.55-3.60 (m, 4H), 4.10 (q, 2H), 4.25 (s, 2H), 7.00 (dd, 1H), 7.05 (dd, 1H), 7.15 (d, 1H), 7.75 (d, 1H), 8.10 (br s, 1H), 8.40 (dd, 1H). MS: ESI (+ve) (Method C): 534 (M+H)+, Retention time 4.3 min
Preparation 5d: {1-[3-chloro-4-(morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2- methylindolizin-3-yl}acetic acid
The title compound was prepared by the method of Preparation 2d {1-[3-chloro-4- (morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2-methylindolizin-3-yl}acetic acid ethyl ester
1H NMR (DMSO-d6): δ 2.20 (s, 3H), 3.05-3.10 (m, 4H), 3.55-3.60 (m, 4H), 4.15 (s, 2H), 7.00 (dd, 1 H), 7.05 (dd, 1 H), 7.20 (d, 1H), 7.75 (d, 1H), 8.10 (m, 1 H), 8.40 (dd, 1H). MS: ESI (+ve) (Method C): 506 (M+H)+, Retention time 3.5 min
Example 6: [7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3- yl]acetic acid
Figure imgf000021_0001
Preparation 6a: [7-cyano-1 -(6-f luoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl]acetic acid ethyl ester
The title compound was prepared by the method of Preparation 1g using (7-cyano- 2-methylindolizin-3-yl)acetic acid ethyl ester and 6-fluoroquinoline-2-carbaldehyde. MS: ESI (+ve) (Method B): 402 (M+H)+, Retention time 3.7 min.
Preparation 6b: [7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl]acetic acid
A solution of [7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl]acetic acid ethyl ester (0.13 g) in tetrahydrofuran (10 mL) was treated with 1.0 M aqueous lithium hydroxide solution (1.0 mL) and the resulting mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, acidified by the addition of 1.0 M aqueous hydrochloric acid and then extracted with ethyl acetate. The combined extracts were dried over magnesium sulfate and the solvent removed under reduced pressure to afford title compound as a bright yellow solid, 0.064 g.
1H NMR (DMSO-d6): δ 2.15 (s, 3H), 3.95 (s, 2H), 4.45 (s, 2H), 6.70 (dd, J = 1.6, 7.4 Hz, 1 H), 7.30 (d, J = 8.4 Hz, 1 H), 7.65 (dt, J = 2.8, 8.8 Hz, 1H), 7.70 (dd, J = 2.8, 9.4 Hz, 1H), 8.00 (dd, J = 5.5, 9.4 Hz, 1 H), 8.10 (d, J = 7.4 Hz, 1 H), 8.20 (d, J = 8.4 Hz, 1H), 8.35 (s, 1 H). MS: ESI (+ve) (Method A): 374 (M+H)+, Retention time 9.0 min.
Biological Methods
Compounds of the invention were tested using the following biological test methods to determine their ability to displace PGD2 from the CRTH2 receptor and for their ability to antagonise the functional effects of PGD2 at the CRTH2 receptor.
Radioligand Binding Assay The receptor binding assay is performed in a final volume of 200 μl_ binding buffer [10 mM BES (pH 7.4), 1 mM EDTA, 10 mM manganese chloride, 0.01 % BSA] and 1 nM [3H]-PGD2 (Amersham Biosciences UK Ltd). Ligands are added in assay buffer containing a constant amount of DMSO (1 % by volume). Total binding is determined using 1 % by volume of DMSO in assay buffer and non-specific binding is determined using 10 μM of unlabeled PGD2 (Sigma). Human embryonic kidney (HEK) cell membranes (3.5 μg) expressing the CRTH2 receptor are incubated with 1.5 mg wheatgerm agglutinin SPA beads and 1 nM [3H]-PGD2 (Amersham Biosciences UK Ltd) and the mixture incubated for 3 hours at room temperature. Bound [3H]-PGD2 is detected using a Microbeta TRILUX liquid scintillation counter (Perkin Elmer). Compound IC50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC50 calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation.
Functional Assay
GTPΎS Assay
The GTPγS Assay is performed in a final volume of 200 mL assay buffer (2OmM HEPES pH 7.4, 1OmM MgCI2, 10OmM NaCI, 10μg/mL saponin). DMSO concentrations are kept constant at 1% by volume. Human embryonic kidney (HEK) cell membranes (3.5 μg) expressing the CRTH2 receptor are incubated with the compounds for 15 min at 30° C prior to addition of PGD2 (3OnM final concentration) and GTP (10μM final concentration). The assay solutions are then incubated for 30 minutes at 30° C, followed by addition of [35S]-GTPγS (0.1 nM final concentration). The assay plate is than shaken and incubated for 5 minutes at 30°C. Finally, SPA beads (Amersham Biosciences, UK) are added to a final concentration of 1.5mg/well and the plate shaken and incubated for 30 minute at 30° C. The sealed plate is centrifuged at 1000g for IOmins at 30oC and the bound [35S]-GTPγS is detected on Microbeta scintillation counter (Perkin Elmer). Compound IC50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC50 calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation.
Biological Results:
The compounds of the Examples above were tested in the CRTH2 radioligand binding and GTPγS functional assays described above; the compounds all have IC50 values of less than 1 μM in both assays. For example, the compound of Example 1 had an IC50 value of 58 nM in the CRTH2 radioligand binding assay, and the compound of Example 6 had an IC50 value of 19 nM in that assay..

Claims

Claims:
1. A compound selected from the group consisting of:
{7-cyano-2-methyl-1-[4-(mόrpholine-4-sulfonyl)benzyl]indolizin-3-yl}acetic acid,
[1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl]acetic acid,
{1-[3-chloro-4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}ar:ptio acid,
[1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl]acetic acid,
{1-[3-chloro-4-(morpholine-4-sulfonyl)phenylsulfanyl]-7-cyano-2-methylindolizin-3- yljacetic acid,
[7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindoIizin-3-yl]acetic acid,
and salts, N-oxides, hydrates and solvates thereof.
2. A compound as claimed in claim 1 for use in therapy.
3. A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
4. Use of a compound as claimed in claim 1 for the manufacture of a composition for the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis.
5. Use of a compound as claimed in claim 1 for the manufacture of a composition for the treatment of psoriasis, atopic and non-atopic dermatitis Crohn's disease, ulcerative colitis, or irritable bowel disease.
6. A method of treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis, comprising administering to a patient suffering such disease an effective amount of a compound as claimed in claim 1.
7. A method of treatment of psoriasis, atopic or non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease, comprising administering to a patient suffering such disease an effective amount of a compound as claimed in claim 1.
PCT/GB2007/000996 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists WO2008113965A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US12/530,929 US20100137300A1 (en) 2007-03-21 2007-03-21 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
EA200970875A EA200970875A1 (en) 2007-03-21 2007-03-21 Derivatives of Indo-Isonic Acid Acid as an Antagonist of CRTH2
MX2009010068A MX2009010068A (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists.
CA002681409A CA2681409A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists
AU2007349641A AU2007349641A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as CRTH2 antagonists
EP07732088A EP2136804A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists
JP2009554075A JP2010522149A (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as CRTH2 antagonists
CN200780052278A CN101678009A (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as CRTH2 antagonists
PCT/GB2007/000996 WO2008113965A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists
BRPI0721477-4A BRPI0721477A2 (en) 2007-03-21 2007-03-21 Acetic indolizine derivatives as crth2 antagonists
IL201090A IL201090A0 (en) 2007-03-21 2009-09-21 Indolizine acetic acid derivatives as crth2 antagonists
NO20093039A NO20093039L (en) 2007-03-21 2009-09-22 Indolizinedacetic acid derivatives such as CRTH2 antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2007/000996 WO2008113965A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists

Publications (1)

Publication Number Publication Date
WO2008113965A1 true WO2008113965A1 (en) 2008-09-25

Family

ID=38436764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000996 WO2008113965A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists

Country Status (12)

Country Link
US (1) US20100137300A1 (en)
EP (1) EP2136804A1 (en)
JP (1) JP2010522149A (en)
CN (1) CN101678009A (en)
AU (1) AU2007349641A1 (en)
BR (1) BRPI0721477A2 (en)
CA (1) CA2681409A1 (en)
EA (1) EA200970875A1 (en)
IL (1) IL201090A0 (en)
MX (1) MX2009010068A (en)
NO (1) NO20093039L (en)
WO (1) WO2008113965A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044134A1 (en) * 2007-10-05 2009-04-09 Argenta Discovery Limited Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases
EP2327693A1 (en) 2007-12-14 2011-06-01 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9879006B2 (en) 2014-03-17 2018-01-30 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES421284A1 (en) * 1973-12-07 1976-04-16 Farmasimes S A Procedure for the preparation of derivatives of pirrocolinacetic acids. (Machine-translation by Google Translate, not legally binding)
WO2003101961A1 (en) * 2002-05-30 2003-12-11 Astrazeneca Ab Novel substituted indoles
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006136859A2 (en) * 2005-06-24 2006-12-28 Argenta Discovery Limited Indoli zine derivatives and their use as crth2 antagonists
WO2007031747A1 (en) * 2005-09-14 2007-03-22 Argenta Discovery Limited Imdolizine derivatives as ligands of the crth2 receptor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES421284A1 (en) * 1973-12-07 1976-04-16 Farmasimes S A Procedure for the preparation of derivatives of pirrocolinacetic acids. (Machine-translation by Google Translate, not legally binding)
WO2003101961A1 (en) * 2002-05-30 2003-12-11 Astrazeneca Ab Novel substituted indoles
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006136859A2 (en) * 2005-06-24 2006-12-28 Argenta Discovery Limited Indoli zine derivatives and their use as crth2 antagonists
WO2007031747A1 (en) * 2005-09-14 2007-03-22 Argenta Discovery Limited Imdolizine derivatives as ligands of the crth2 receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASAGRANDE C ET AL: "INDOLIZINE ANALOGUES OF INDOMETHACIN", FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 26, 1971, pages 1059 - 1073, XP009074694, ISSN: 0430-0920 *
VINCENT S. VENTURELLA: "Methoxyl and Glyoxyl Derivatives of Several Substituted Phenylindolizines", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 53, no. 10, 1964, pages 1166 - 1169, XP002449258 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044134A1 (en) * 2007-10-05 2009-04-09 Argenta Discovery Limited Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases
EP2327693A1 (en) 2007-12-14 2011-06-01 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012069175A1 (en) 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9879006B2 (en) 2014-03-17 2018-01-30 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US10301309B2 (en) 2014-03-17 2019-05-28 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms

Also Published As

Publication number Publication date
EP2136804A1 (en) 2009-12-30
IL201090A0 (en) 2010-05-17
BRPI0721477A2 (en) 2013-01-15
NO20093039L (en) 2009-11-17
CA2681409A1 (en) 2008-09-25
JP2010522149A (en) 2010-07-01
CN101678009A (en) 2010-03-24
EA200970875A1 (en) 2010-04-30
US20100137300A1 (en) 2010-06-03
AU2007349641A1 (en) 2008-09-25
MX2009010068A (en) 2010-02-24

Similar Documents

Publication Publication Date Title
AU2007350688B2 (en) Quinoline derivatives as CRTH2 receptor ligands
EP2327693B9 (en) Indoles and their therapeutic use
US20100010034A1 (en) Crth2 antagonists
US20090163534A1 (en) Indolizine Derivatives
US20100137300A1 (en) Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
US20080306109A1 (en) Indolizine Derivatives as Ligands of the Crth2 Receptor
US20100093751A1 (en) Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor
US20110060026A1 (en) Indoles Active on CRTH2 Receptor
WO2009044147A1 (en) Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases
WO2010142934A1 (en) Indole derivatives as ligands of crth2 receptors
US20100144787A1 (en) Quinolines and Their Therapeutic Use
WO2009044134A1 (en) Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases
WO2009060209A1 (en) 6,6-fused bicyclic aromatic compounds and their therapeuti use
WO2010040992A1 (en) Quinoline derivatives having dp and / or crth2 receptor activity
NZ580310A (en) Quinoline derivatives as crth2 receptor ligands

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780052278.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732088

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007732088

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009554075

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 6011/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/010068

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2681409

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201090

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12009501814

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 6109/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007349641

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 580309

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200970875

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2007349641

Country of ref document: AU

Date of ref document: 20070321

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12530929

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0721477

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090918